SARMs Store sells research compounds only. Nothing on this page is medical advice or an instruction for human use, and nothing here should be read as a recommendation to obtain or consume yohimbine.
Yohimbine is one of the oldest compounds in the fat loss conversation and one of the most awkward from a regulatory point of view. It has a genuine pharmacological mechanism, a small but real human research base, a well documented side effect profile, and a UK legal position considerably less simple than the internet suggests. This page sets out what the research shows and where the regulatory picture stands, with deliberate hedging where the position is genuinely unsettled.
What yohimbine is
In short: Yohimbine is an indole alkaloid from the bark of the West African tree Pausinystalia johimbe that blocks alpha-2 adrenergic receptors. Yohimbine hydrochloride is the purified salt and is not the same thing as crude yohimbe bark extract.
Yohimbine is an indole alkaloid found in the bark of the West African tree Pausinystalia johimbe, and also present in Rauwolfia species. Yohimbine hydrochloride is the purified salt of that alkaloid, as distinct from crude yohimbe bark extract, which contains a variable and often poorly characterised mixture of alkaloids. The two are not interchangeable, and much of the confusion in the popular literature comes from treating them as though they are.
Pharmacologically, yohimbine is a competitive antagonist at the alpha-2 adrenergic receptor. Alpha-2 receptors on fat cells act as a brake on lipolysis: when noradrenaline binds them, the breakdown of stored triglyceride is inhibited. Beta-adrenergic receptors do the opposite. Blocking the alpha-2 side removes the brake, which in theory allows greater fat mobilisation from tissue rich in alpha-2 receptors. Yohimbine also acts at alpha-1 and serotonergic receptors and crosses the blood-brain barrier, which accounts for much of its side effect profile.
What the research found
In short: A small human literature shows that yohimbine increases fat mobilisation. One 21 day study in professional footballers reported a lower body fat percentage with no change in performance, and studies in obesity have been inconsistent.
Lipid mobilisation in humans. Galitzky and colleagues, publishing in the European Journal of Clinical Investigation in 1988, demonstrated that yohimbine increases lipid mobilisation in human subjects, establishing that the alpha-2 blockade seen in isolated fat cells translates into a measurable systemic effect. Related work by Berlan and colleagues examined the same mechanism in vivo and confirmed increases in circulating free fatty acids and glycerol.
Body fat in trained athletes. The most cited applied study is Ostojic, in Research in Sports Medicine in 2006. Professional male soccer players received yohimbine or placebo for 21 days alongside their normal training. Body fat percentage fell significantly in the yohimbine group, from roughly nine per cent to around seven per cent, while body mass, muscle mass and a battery of physical performance measures showed no significant difference between groups. That last point is routinely dropped from marketing summaries: a body composition effect without a performance effect.
Obesity and energy restriction. Earlier work examined yohimbine alongside energy-restricted diets in obese participants, with inconsistent results. Some trials reported greater weight loss, others found no difference against placebo. The dataset is small and does not support strong conclusions.
Regional fat distribution. Alpha-2 receptor density does differ between fat depots, which is the basis of the claim that yohimbine targets stubborn areas. The receptor biology is real. That it produces visible regional differences in humans has not been convincingly demonstrated in controlled trials.
Side effects reported
In short: Yohimbine raises sympathetic nervous activity, and the reported effects include anxiety, raised blood pressure, a fast heart rate, tremor and poor sleep.
Yohimbine’s adverse effect profile is the main reason its regulatory position is contested. Because it is a centrally active alpha-2 antagonist, it increases sympathetic outflow. Reported effects include anxiety, agitation and panic reactions, raised blood pressure, tachycardia and palpitations, tremor, sweating, nausea, headache and insomnia.
Anxiety responses are dose-related and were documented in psychiatric research that used yohimbine deliberately as a panic-provoking agent, which tells you a great deal about its central effects. Case reports of hypertensive episodes and more serious cardiovascular events following high-dose or poorly characterised yohimbe products exist in the toxicology literature. Interaction with monoamine oxidase inhibitors and with other stimulants is a recognised concern.
Comparison with related compounds
In short: Unlike caffeine or synephrine, yohimbine works by removing a brake on fat breakdown rather than by direct stimulation.
Yohimbine is often grouped with caffeine, synephrine and other thermogenic ingredients, but the mechanism differs. Caffeine works largely through adenosine receptor antagonism and phosphodiesterase inhibition; synephrine is a beta-adrenergic agonist. Yohimbine is the only widely discussed compound in the group that works by removing an inhibitory brake rather than by direct stimulation, which is why combined products tend to amplify the cardiovascular effects of all of them. Rauwolscine, sold as alpha-yohimbine, is a stereoisomer with a similar profile and an even thinner research base.
Legal status in the UK, 2026
In short: Yohimbine is not a controlled drug in the UK, but it is not a licensed medicine either, and its status as a food ingredient is contested.
This is the part that needs care. Yohimbine is not a controlled substance under the Misuse of Drugs Act 1971. Nor is it a licensed medicine in the United Kingdom: there is no UK marketing authorisation for a yohimbine product. Historically, yohimbine hydrochloride has appeared in UK medicines legislation as a substance restricted to prescription, and the MHRA has taken the position that products containing yohimbine presented for effects on the body fall to be treated as unauthorised medicinal products.
Its acceptability as a food supplement ingredient is contested, has been assessed differently across European jurisdictions, and remains under regulatory review. Anyone selling, importing or intending to use yohimbine in the UK should check the current MHRA and Food Standards Agency positions directly rather than relying on any summary, because the position has moved and may move again. For athletes, yohimbine is not currently on the WADA Prohibited List, but stimulant listings under section S6 change and should be verified against the current list.
How to check a supplier
In short: The key check is a batch-specific certificate of analysis that identifies the material as yohimbine hydrochloride rather than crude bark extract.
Ask for the certificate of analysis for the specific batch rather than a generic document, with identity confirmed by HPLC or LC-MS, a stated purity figure, and a batch number matching the bottle. The distinction between characterised yohimbine hydrochloride and crude bark extract is exactly what a real certificate settles and a marketing page does not; analytical surveys of yohimbe-labelled supplements have found alkaloid content varying wildly from the label, including products containing almost none of what they claimed.
Look also for UK manufacturing and transparent labelling of every ingredient with amounts. Dexterz Labs Shred Series is manufactured in the UK, 60 capsules per bottle, and batch certificates of analysis are being published on the product page as testing is completed.
Frequently asked questions
Is yohimbine the same as yohimbe bark? No. Yohimbine hydrochloride is a purified single alkaloid. Yohimbe bark extract is a crude mixture in which yohimbine content varies enormously between products.
What did the Ostojic study actually show? A significant fall in body fat percentage in professional soccer players over 21 days, with no significant change in body mass, muscle mass or any measure of physical performance.
Does yohimbine target stubborn fat? Alpha-2 receptor density does differ between fat depots, which is the theoretical basis for the claim, but controlled human trials have not demonstrated a clear regional effect.
Why does yohimbine cause anxiety? It is a centrally active alpha-2 antagonist and increases sympathetic outflow. It was used deliberately in psychiatric research as a panic-provoking agent.
Is yohimbine legal to sell in the UK? Its status is contested. It is not controlled under the Misuse of Drugs Act, it is not a licensed medicine, and the MHRA has treated products presented for physiological effect as unauthorised medicines. Check the current regulatory position directly.
Is yohimbine banned in sport? It is not currently named on the WADA Prohibited List, but stimulant listings change and athletes should check the current list and use batch-tested products.
Related reading
- SARMs for fat loss: what the research supports
- Cardarine (GW-501516): what the studies show
- SARMs results: what the trials measured
- Third-party testing: how to read a certificate of analysis
- Browse the range: supplements range
Research product: Dexterz Labs Shred Series, 60 capsules
Sources
- Ostojic SM, Res Sports Med 2006;14:289-299. PubMed 17214405
- Galitzky J et al., Eur J Clin Invest 1988;18:587-594. PubMed 2906290
- Berlan M et al., studies on alpha-2 adrenergic control of lipid mobilisation in humans.
- Charney DS et al., Arch Gen Psychiatry 1984;41:751-763 (yohimbine and anxiety response). PubMed 6742977
- MHRA and Food Standards Agency guidance.
- WADA Prohibited List 2026.